Researcher
Fritz Offner
- Keywords:tumor immunotherapy, real world data, bispecific antibodies, clinical trials, myeloma, Lymphoma
- Disciplines:Cancer epidemiology, Applied immunology, Medical epigenomics, Clinical hematology, Medical genomics, Diagnostic radiology, Hematology, Analysis of next-generation sequence data, Cancer biology
Affiliations
- Department of Internal Medicine and Pediatrics (Department)
Member
From1 Oct 2018 → Today - Department of Internal medicine (Department)
Member
From1 Oct 2000 → 30 Sep 2018
Projects
1 - 5 of 5
- Universal, cost-effective and hypersensitive open-source technology platform for liquid biopsy based on methylome profiling of circulating DNA.From1 Jan 2024 → TodayFunding: BOF - projects
- Optimisation of CD70-targeted adoptive cell therapyFrom1 Nov 2023 → TodayFunding: FWO Strategic Basic Research Grant
- Optimising CD70-specific T cell therapy for solitary and haematological malignanciesFrom1 Nov 2022 → 31 Oct 2023Funding: BOF - doctoral mandates
- Chimeric antigen receptor unconventional T cell therapy (CAR-uT) for the treatment of solid tumorsFrom1 Nov 2022 → TodayFunding: FWO Strategic Basic Research Grant
- Cell-free nucleic acid profiling in diffuse large B-cell lymphoma: a molecular guidance to precision medicineFrom1 Oct 2022 → 31 Oct 2022Funding: BOF - doctoral mandates
Publications
1 - 10 of 169
- The iR2 regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL : a multicentre, non-randomised, open-label phase 2 study(2023)
Authors: Radhakrishnan Ramchandren, Peter Johnson, Nilanjan Ghosh, Jia Ruan, Kirit M. Ardeshna, Roderick Johnson, Gregor Verhoef, David Cunningham, Sven de Vos, Shireen Kassam, et al.
- Efficacy of forimtamig, a GPRC5DxCD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM) : analysis of patient and disease-related factors associated with responses(2023)Volume: 23
Authors: Simon Harrison, Caroline Hasselbalch Riley, Salomon Manier, Sung-Soo Yoon, Antonio Pinto, Titouan Cazaubiel, Anna Guidetti, Rakesh Popat, Cyrille Touzeau, Enrique Ocio, et al.
Pages: S3 - S4 - Single cell multi-omic dissection of response and resistance to chimeric antigen receptor T cells against BCMA in relapsed multiple myeloma(2023)Volume: 23
Authors: Simon Harrison, Caroline Hasselbalch Riley, Salomon Manier, Sung-Soo Yoon, Antonio Pinto, Titouan Cazaubiel, Anna Guidetti, Rakesh Popat, Cyrille Touzeau, Enrique Ocio, et al.
Pages: S3 - S3 - Exploring the cell-free total RNA transcriptome in diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma patients as biomarker source in blood plasma liquid biopsies(2023)
Authors: Philippe Decruyenaere, Edoardo Giuili, Kimberly Verniers, Jasper Anckaert, Katrien De Grove, Malaïka Van der Linden, Dries Deeren, Jo Van Dorpe, Fritz Offner, Jo Vandesompele
- ELARA trial update : long-term clinical outcomes and correlative efficacy analyses of tisagenlecleucel in patients with relapsed/refractory follicular lymphoma (R/R FL)(2023)Volume: 23
Authors: Nathan Fowler, Martin Dreyling, Michael Dickinson, Joaquin Martinez-Lopez, Arne Kolstad, Jason Butler, Monalisa Ghosh, Leslie Popplewell, Julio Chavez, Emmanuel Bachy, et al.
Pages: S534 - S535 - Subcutaneous epcoritamab with R-CHOP in previously untreated high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma : updated results from EPCORE NHL-2(2023)Volume: 98
Authors: Lorenzo Falchi, Roost Michael Clausen, Fritz Offner, Sven de Vos, Brody D. Joshua, Linton M. Kim, Sylvia Snauwaert, Raul Cordoba, Toshihiko Oki, Irina Bykhovski, et al.
Pages: S50 - S50 - Glofitamab monotherapy induces high complete response rates in patients with heavily pretreated Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL)(2023)Volume: 46
Authors: M. Dreyling, T. Phillips, M. Dickinson, F. Morschhauser, E. Bachy, M. Crump, M. Trneny, N. L. Bartlett, J. Zaucha, T. Wrobel, et al.
Pages: 23 - 24 - Epcoritamab plus R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma : updated EPCORE NHL-2 data(2023)Volume: 23
Authors: Lorenzo Falchi, Michael Roost Clausen, Fritz Offner, Sven de Vos, Joshua Brody, Kim M. Linton, Sylvia Snauwaert, Raul Cordoba, Jun Wu, Irina Bykhovski, et al.
Pages: S431 - S432 - Glofitamab monotherapy induces high complete response rates in patients with heavily pretreated relapsed/ refractory mantle cell lymphoma(2023)Volume: 98
Authors: Tycel Phillips, Michael Dickinson, Franck Morschhauser, Emmanuel Bachy, Michael Crump, Marek Trneny, Bartlett L. Nancy, Jan Zaucha, Tomasz Wrobel, Fritz Offner, et al.
Pages: S52 - S53 - Long-term clinical outcomes and correlative efficacy analyses in patients (Pts) with relapsed/refractory (r/r) follicular lymphoma (FL) treated with tisagenlecleucel in the ELARA Trial(2023)Volume: 46
Authors: M. Dreyling, M. Dickinson, J. Martinez-Lopez, A. Kolstad, J. Butler, M. Ghosh, L. Popplewell, J. C. Chavez, E. Bachy, K. Kato, et al.
Pages: 306 - 308
Linked dataset
1 - 1 of 1